SCHEMBL17757482

SCHEMBL17757482

NC(=O)CNc1cc2c(cc1Cl)NC1(CCNCC1)C(NCc1cccc(Cl)c1)=N2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACAT2 Q9BWD1 1/20 0.39
▸ RPS6KB1 P23443 2/20 0.35
▸ CD38 P28907 1/20 0.35
▸ CCNT1 O60563 2/20 0.35
▸ AKT1 P31749 1/20 0.35
▸ MAOB P27338 2/20 0.34
▸ HTR6 P50406 2/20 0.34
▸ MRGPRX4 Q96LA9 1/20 0.34
▸ HDAC3 O15379 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ IGF1R P08069 1/20 0.33
▸ VNN1 O95497 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ CYP3A4 P08684 2/20 0.32
▸ SSTR1 P30872 1/20 0.32
▸ SSTR4 P31391 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17757975 0.97 ACAT2 (0.39) ACAT2RPS6KB1CD38CCNT1AKT1
SCHEMBL17758027 0.85 ACAT2 (0.47) ACAT2CCNT1MAOBHTR6HDAC3
SCHEMBL17757760 0.85 ACAT2 (0.44) ACAT2RPS6KB1CD38AKT1MAOB
SCHEMBL17757318 0.84 VNN1 (0.44) ACAT2RPS6KB1CD38AKT1MAOB
SCHEMBL17757763 0.83 ACAT2 (0.41) ACAT2RPS6KB1CD38CCNT1MAOB
SCHEMBL17757277 0.83 ACAT2 (0.44) ACAT2CCNT1MAOBHTR6HDAC3
SCHEMBL17757784 0.82 VNN1 (0.43) ACAT2RPS6KB1CD38AKT1MAOB
SCHEMBL17757776 0.81 ACAT2 (0.48) ACAT2CCNT1MAOBHTR6HDAC3
SCHEMBL17757280 0.81 ACAT2 (0.44) ACAT2CCNT1MAOBHTR6HDAC3
SCHEMBL17757321 0.81 ACAT2 (0.47) ACAT2CCNT1MAOBHTR6HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2020-05-12 — — US disclosed
WO-2016075137-A1 SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2016-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 ACAT2 1935/4885RPS6KB1 909/4885CD38 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback